TY - JOUR
T1 - Epirubicin and cyclophosphamide, methotrexate and fluorouracil as adjuvant therapy for early breast cancer
AU - Poole, Christopher
AU - Earl, HM
AU - Hiller, Louise
AU - Dunn, Janet
AU - Bathers, Sarah
AU - Grieve, RJ
AU - Spooner, David
AU - Agrawal, RK
AU - Fernando, Indy
AU - Brunt, AM
AU - O'Reilly, SM
AU - Crawford, SM
AU - Rea, Daniel
AU - Simmonds, P
AU - Mansi, JL
AU - Stanley, A
AU - Harvey, PG
AU - McAdam, K
AU - Foster, L
AU - Leonard, RCF
AU - Twelves, CJ
PY - 2006/11/2
Y1 - 2006/11/2
N2 - BACKGROUND: The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial examined the efficacy of anthracyclines in the adjuvant treatment of early breast cancer. METHODS: In NEAT, we compared four cycles of epirubicin followed by four cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) with six cycles of CMF alone. In the BR9601 trial, we compared four cycles of epirubicin followed by four cycles of CMF, with eight cycles of CMF alone every 3 weeks. The primary end points were relapse-free and overall survival. The secondary end points were adverse effects, dose intensity, and quality of life. RESULTS: The two trials included 2391 women with early breast cancer; the median follow-up was 48 months. Relapse-free and overall survival rates were significantly higher in the epirubicin-CMF groups than in the CMF-alone groups (2-year relapse-free survival, 91% vs. 85%; 5-year relapse-free survival, 76% vs. 69%; 2-year overall survival, 95% vs. 92%; 5-year overall survival, 82% vs. 75%; P
AB - BACKGROUND: The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial examined the efficacy of anthracyclines in the adjuvant treatment of early breast cancer. METHODS: In NEAT, we compared four cycles of epirubicin followed by four cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) with six cycles of CMF alone. In the BR9601 trial, we compared four cycles of epirubicin followed by four cycles of CMF, with eight cycles of CMF alone every 3 weeks. The primary end points were relapse-free and overall survival. The secondary end points were adverse effects, dose intensity, and quality of life. RESULTS: The two trials included 2391 women with early breast cancer; the median follow-up was 48 months. Relapse-free and overall survival rates were significantly higher in the epirubicin-CMF groups than in the CMF-alone groups (2-year relapse-free survival, 91% vs. 85%; 5-year relapse-free survival, 76% vs. 69%; 2-year overall survival, 95% vs. 92%; 5-year overall survival, 82% vs. 75%; P
UR - http://www.scopus.com/inward/record.url?scp=33750502656&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa052084
DO - 10.1056/NEJMoa052084
M3 - Article
C2 - 17079759
SN - 1533-4406
VL - 355
SP - 1851
EP - 1862
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 18
ER -
